# breast cancer - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 24801
- Completion tokens: 14861
- Reasoning tokens: 0
- Total tokens: 39662
- API requests reported: 2
- Elapsed seconds: 146.342
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 2/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants a comprehensive, multidimensional, evidence-grounded interpretation of prognostic transcriptomic data in breast cancer (overall survival). Let me analyze the data carefully.

**Data Overview:**
- 100 unique genes (input had 106 rows, 6 duplicates)
- 52 risk-associated (HR > 1)
- 48 protective-associated (HR < 1)
- All genes have FDR ≤ 0.01
- HR range: ~0.79 to ~1.26 (modest effect sizes individually, but highly significant)

**Risk-associated genes (HR > 1) - notable ones by program:**

*Cell cycle / mitosis / proliferation:*
- PKMYT1 (HR=1.244) - Wee1-like kinase, G2/M transition
- RACGAP1 (HR=1.224) - Rac GTPase activating protein, cytokinesis
- KIF20A (HR=1.218) - mitotic kinesin
- TROAP (HR=1.210) - trophinin-associated protein
- CDCA5 (HR=1.218) - sororin, cohesin regulator
- TK1 (HR=1.210) - thymidine kinase, DNA synthesis
- TPX2 (HR=1.202) - mitotic spindle
- KIF4A (HR=1.199) - chromosomal kinesin
- UHRF1 (HR=1.209) - epigenetic regulator, cell cycle
- UBE2C (HR=1.210) - ubiquitin conjugating enzyme, APC/C
- POC1A (HR=1.206) - centriolar protein
- CENPO (HR=1.189) - centromere protein
- CCNE2 (HR=1.186) - cyclin E2
- PTTG1 (HR=1.197) - securin
- FEN1 (HR=1.189) - flap endonuclease, DNA replication
- CDC20 (HR=1.191) - APC/C activator
- AURKA (HR=1.189) - aurora kinase A
- ZWINT (HR=1.191) - kinetochore
- NUSAP1 (HR=1.194) - mitotic spindle
- PRC1 (HR=1.186) - protein regulator of cytokinesis
- UBE2S (HR=1.184)
- CKAP2L (HR=1.191) - cytoskeleton-associated
- TIMELESS (HR=1.196) - circadian/S-phase
- GRHL2 (HR=1.217) - transcription factor

*Translation / RNA binding:*
- LARP1 (HR=1.261) - La-related protein, mTOR pathway, translation
- YTHDF1 (HR=1.192) - m6A reader, translation
- RALGAPB (HR=1.207) - Ral GTPase activating protein

*Other / signaling:*
- STIP1 (HR=1.237) - stress-induced phosphoprotein, cochaperone
- GSK3B (HR=1.227) - glycogen synthase kinase
- ATP2A2 (HR=1.238) - SERCA, calcium pump
- EZR (HR=1.227) - ezrin, cytoskeletal linker
- USP30 (HR=1.222) - deubiquitinase
- CPT1A (HR=1.196) - fatty acid oxidation
- GPRC5A (HR=1.202) - orphan GPCR
- WNT7B (HR=1.183) - Wnt ligand
- S100P (HR=1.196) - calcium binding
- ALG3 (HR=1.187) - glycosylation
- DDX41 (HR=1.191) - RNA/DNA helicase
- TBC1D24 (HR=1.188) - GTPase activating
- TBC1D31 (HR=1.195)
- PSMD3 (HR=1.183) - proteasome
- ADGRG1 (HR=1.205) - adhesion GPCR
- FAF2 (HR=1.200) - FAS-associated factor
- HACD3 (HR=1.197) - lipid metabolism
- GPI (HR=1.192) - glucose-6-phosphate isomerase
- CFL1 (HR=1.191) - cofilin, actin
- ZFP91 (HR=1.183) - zinc finger
- TRIB3 (HR=1.191) - pseudokinase, stress response
- MYORG (HR=1.192)
- CATSPERB (HR=1.189)
- RMND5B (HR=1.198)
- UTP23 (HR=1.203)

**Protective genes (HR < 1):**

*Immune / antigen presentation:*
- FCER1A (HR=0.793) - high-affinity IgE receptor
- JCHAIN (HR=0.803) - immunoglobulin joining chain
- CD1C (HR=0.814) - lipid antigen presentation
- CD1E (HR=0.824) - lipid antigen presentation
- FLT3 (HR=0.817) - dendritic cell development
- KLRB1 (HR=0.822) - NK/T cell marker (CD161)
- IL27RA (HR=0.825) - IL-27 receptor
- STAT5A (HR=0.806) - JAK-STAT signaling
- STAT5B (HR=0.837)
- PDGFRA (HR=0.838)

*ECM / basement membrane / mesenchymal:*
- COL17A1 (HR=0.798)
- LAMA2 (HR=0.830) - laminin
- OGN (HR=0.807) - osteoglycin
- OMD (HR=0.829)
- LRFN5 (HR=0.803)
- CLDN11 (HR=0.819) - claudin
- RELN (HR=0.796) - reelin
- DST (HR=0.807) - dystonin
- COL14A1 (HR=0.824)
- ADAMTS8 (HR=0.793)
- MFAP4 (HR=0.834)
- IGFBP6 (HR=0.828)
- PCDH18 (HR=0.825)
- IGSF10 (HR=0.824)
- CPED1 (HR=0.830)
- CBX7 (HR=0.831)
- PROS1 (HR=0.836) - protein S

*Signaling / growth:*
- SPRY2 (HR=0.806) - negative feedback on MAPK
- ITM2A (HR=0.815)
- LEPR (HR=0.820) - leptin receptor
- IGF1 (HR=0.803)
- CDKN2C (HR=0.808) - p18-INK4c, CDK inhibitor
- CCND2 (HR=0.838) - cyclin D2
- RBBP8 (HR=0.835)
- MOB3B (HR=0.821)
- N4BP2L1 (HR=0.820)
- POLR3GL (HR=0.839)
- DMAC1 (HR=0.828)
- CLIC6 (HR=0.826)
- GLA (HR=0.819)
- GSTK1 (HR=0.837)
- PPIL3 (HR=0.810)
- RLN2 (HR=0.824) - relaxin
- AK3 (HR=0.814) - adenylate kinase
- TP63 (HR=0.810) - p63, basal/myoepithelial
- ABCB1 (HR=0.815) - MDR1/P-glycoprotein
- RPA2 (HR=0.832)

**Core Biological Programs (let me identify the major themes):**

1. **Cell cycle / mitotic proliferation program (risk)** - The strongest signal. Many genes involved in G2/M, spindle, chromosome segregation, APC/C, DNA replication. GO: Mitotic nuclear division; KEGG: Cell cycle.

2. **Adaptive immunity / anti-tumor immune program (protective)** - Multiple immune markers including antigen presentation (CD1C, CD1E), IgE receptor (FCER1A), B cell (JCHAIN), NK/T cell (KLRB1), dendritic cell (FLT3), IL-27 signaling (IL27RA), STAT5.

3. **ECM / basement membrane / myoepithelial differentiation program (protective)** - Multiple collagen/laminin/ECM genes (COL17A1, LAMA2, OGN, COL14A1, ADAMTS8, RELN, DST, MFAP4, IGFBP6, CLDN11), plus TP63 (myoepithelial marker).

4. **Translation / mTOR / RNA metabolism program (risk)** - LARP1 (mTOR substrate), YTHDF1 (m6A reader), EZR (translation-associated), RALGAPB (signaling).

5. **Metabolic / oxidative stress program (mixed)** - CPT1A (FAO, risk), GPI (glycolysis, risk), GSK3B (risk), GSTK1 (protective), AK3 (protective), TRIB3 (risk).

6. **Signaling / membrane trafficking (risk)** - ATP2A2 (Ca2+), EZR, USP30, ADGRG1, GPRC5A, WNT7B.

Let me consolidate into 5:

1. Mitotic/cell cycle proliferation (risk)
2. Adaptive anti-tumor immunity (protective)
3. ECM/differentiation/myoepithelial (protective)
4. RNA/translation/epigenetic (risk) - LARP1, YTHDF1, UHRF1, etc.
5. Calcium/cytoskeletal signaling (risk) - ATP2A2, EZR, GSK3B, STIP1, etc.

**Key genes/modules:**

1. **AURKA / TPX2 / KIF4A / PRC1 / NUSAP1** - mitotic spindle module (risk)
2. **CDC20 / UBE2C / UBE2S / PTTG1** - APC/C ubiquitin module (risk)
3. **CCNE2 / CCND2 / CDKN2C** - cell cycle CDK module (mixed)
4. **CD1C / CD1E / FCER1A / FLT3 / JCHAIN / KLRB1** - antigen presentation/immune module (protective)
5. **STAT5A / STAT5B / IL27RA** - JAK-STAT5 module (protective)
6. **TP63 / LAMA2 / COL17A1 / COL14A1 / DST / RELN** - basal/myoepithelial differentiation (protective)
7. **LARP1 / YTHDF1 / UHRF1** - translation/epitranscriptome (risk)
8. **GSK3B / STIP1 / ATP2A2 / EZR** - signaling/cytoskeleton (risk)
9. **PKMYT1 / RACGAP1 / KIF20A / CDCA5** - G2/M and cytokinesis (risk)
10. **CPT1A / GPI / GSK3B** - metabolic (risk)

**Network evidence from retrieval:**
- PLK1 hub: AURKA, CDC20, KIF20A, PKMYT1 (STRING)
- TPX2 hub: AURKA, KIF4A, NUSAP1, PRC1
- ANAPC2 (APC/C): CDC20, UBE2C, UBE2S
- BUB1B: CDC20, KIF4A, ZWINT
- CDK4: CCND2, CCNE2, CDKN2C
- STAT3: FLT3, LEPR, STAT5A, STAT5B

**Validation priorities:**

1. **AURKA/TPX2/PRC1 mitotic module as therapeutic target** - therapeutic target
2. **Mitotic proliferation signature as prognostic biomarker** - biomarker
3. **Immune signature (CD1C, FCER1A, JCHAIN) for immune-hot tumors** - biomarker / confounding check
4. **LARP1-YTHDF1 translation axis in aggressive BC** - mechanistic hypothesis / therapeutic target
5. **TP63/myoepithelial/ECM program as luminal/basal marker** - confounding or composition check

**Limitations:**
1. Tissue/cell-composition effects (immune cells in tumor microenvironment)
2. Tumor purity / stromal contamination
3. Subtype confounding (luminal vs basal vs HER2)
4. Treatment exposure heterogeneity
5. Association vs causation (HR models don't establish causality)
6. Modest individual HRs (1.18-1.26) - may need combined signature
7. Batch/platform effects possible

Let me now write a comprehensive response. I need to be thorough but focused, following the structure requested but integrating naturally. The system instructions say to use the statistical ledger as authoritative for effects, treat external evidence as contextual, distinguish direct from external validation, and never claim enrichment without computation.

I notice there are no explicit GSEA/enrichment statistics computed in this batch - just "retrieved recurrence" which is GO/KEGG term lists from database lookups. I should be careful about claiming "enrichment" - I'll say "the selected genes fall within pathways/modules consistent with..." rather than "enriched."

The evidence pack notes "INDEPENDENT COHORT VALIDATION: status=not_available" - so I must say external statistical validation was not performed.

Also, the program lists in the batch section show "selected_genes: GO: Positive Regulation Of Mitotic Nuclear Division (GO:0045840)..." - these are precomputed pathway annotations from the RAG, not enrichment statistics. I'll use them as pathway co-membership evidence.

Let me structure the response carefully and write it now.</think>

# Multidimensional Prognostic Interpretation: Breast Cancer Overall Survival

## 1. Overall biological interpretation

The cohort divides cleanly into two prognostic poles. **Risk-associated genes (52; HR ≈ 1.18–1.26)** are dominated by cell-cycle/mitotic machinery, translational/epigenetic regulators, and cytoskeletal-signaling effectors, while **protective-associated genes (48; HR ≈ 0.79–0.84)** cluster around adaptive immunity, ECM/basement-membrane/myoepithelial differentiation, and negative feedback on proliferative signaling. The HR magnitudes per gene are modest, but every gene passed FDR ≤ 1.7 × 10⁻⁶, so the signal is statistically strong *within this dataset*; the prognostic picture is reinforced by the consistency of the direction across functionally coherent gene sets rather than by any single large-effect gene.

In practical terms: shorter OS is associated with a transcriptional state resembling an actively dividing, translationally and metabolically re-wired tumor (mitotic checkpoint, mTOR-coupled translation, m⁶A readers, Ca²⁺/cytoskeleton remodeling), whereas longer OS is associated with a state in which the tumor expresses programs of lymphoid/myeloid infiltration (antigen presentation, IgE receptor, JCHAIN, NK/T markers) and basal-myoepithelial/ECM differentiation (collagen XVII/laminin α2/reelin/p63). These are co-occurring prognostic programs, not independent predictors, and the immune and mesenchymal signals may partly reflect non-malignant cell composition within the tumor sample (see §6).

> Important framing: no independent-cohort survival statistic was supplied. All HR/P/FDR values below are from the uploaded analysis; pathway, interaction, drug and literature records are used as contextual plausibility, not as replication.

---

## 2. Core biological programs (≤5)

### Program A — Mitotic proliferation and spindle/APC-C⁰ checkpoint (risk-associated)

- **Direction:** worse OS.
- **Representative supporting genes (risk HRs):** PKMYT1 (1.244), RACGAP1 (1.224), KIF20A (1.218), CDCA5 (1.218), TROAP (1.210), TPX2 (1.202), KIF4A (1.199), NUSAP1 (1.194), CENPO (1.189), CKAP2L (1.191), PRC1 (1.186), ZWINT (1.191), PTTG1 (1.197), CDC20 (1.191), AURKA (1.189), UBE2C (1.210), UBE2S (1.184), CCNE2 (1.186), TK1 (1.210), FEN1 (1.189), UHRF1 (1.209), TIMELESS (1.196), POC1A (1.206).
- **Standardized pathway references:** GO:0045840 "positive regulation of mitotic nuclear division," GO:1904668 / GO:0051443 "positive regulation of ubiquitin-protein ligase/transferase activity"; KEGG "Cell cycle," "Oocyte meiosis."
- **Why these genes together indicate the program:** This is the single largest cohesive block in the gene set. Aurora-A kinase (AURKA), its spindle activator TPX2, the kinesins KIF4A/KIF20A, the centralspindlin component RACGAP1, the kinesin-like PRC1, the centromere/spindle proteins CENPO/ZWINT/NUSAP1 and the DNA-replication effectors TK1/FEN1/TIMELESS all converge on G2/M transit, kinetochore/spindle assembly, chromosome segregation and DNA synthesis. The APC/C co-activator CDC20 with its E2 enzymes UBE2C/UBE2S and the securin PTTG1 add ubiquitin-driven anaphase onset and cyclin-A destruction. UHRF1 and TIMELESS couple replication to epigenetic maintenance.
- **Strength and limitations:** Very strong in-cohort: ~25/52 risk genes fall in this program with concordant direction and very low FDR. The retrieved network evidence (STRING) places AURKA, CDC20, KIF20A, PKMYT1 as PLK1-neighbors; AURKA/KIF4A/NUSAP1/PRC1 as TPX2-neighbors; CDC20/UBE2C/UBE2S as ANAPC2 (APC/C) neighbors — these are *co-membership / physical neighborhood* signals, not functional assays. The program does not by itself discriminate among proliferating luminal, HER2⁺ or basal-like tumors, and proliferation is a near-universal adverse prognostic feature, so its novelty for BC is limited.

### Program B — Adaptive anti-tumor immunity (protective-associated)

- **Direction:** better OS.
- **Representative supporting genes (protective HRs):** FCER1A (0.793), JCHAIN (0.803), CD1C (0.814), CD1E (0.824), FLT3 (0.817), KLRB1 (0.822), IL27RA (0.825), STAT5A (0.806), STAT5B (0.837).
- **Pathway references:** Reactome/QuickGO: antigen processing and presentation (CD1 family — lipid antigens), FcεRI signaling (FCER1A), IL-27 signaling (IL27RA→STAT5), JAK-STAT5 cascade.
- **Why these genes together indicate the program:** CD1C/CD1E are dendritic-cell lipid-antigen presenters; FCER1A marks FcεRI-bearing myeloid cells; JCHAIN is the B-cell/plasma-cell immunoglobulin joining chain; KLRB1 (CD161) marks NK and innate-like T cells; FLT3 is a DC development receptor; IL27RA pairs with STAT5A/B for IL-27–driven lymphocyte signaling. Combined, these markers identify a *lymphoid- and DC-rich* microenvironment, the canonical "immune-hot" phenotype repeatedly linked to favorable BC outcome and immunotherapy responsiveness.
- **Strength and limitations:** Strong within-cohort direction (8/48 protective genes, all top-ranked), biologically coherent and consistent with the BC immune-prognosis literature (CIViC/clinicaltrials records return for some, but the protective direction in this dataset is the only direct evidence). Critical caveat: tumor-infiltrating immune cells are non-malignant; their signal may reflect *immune infiltration rather than tumor-intrinsic phenotype* (see §6).

### Program C — ECM, basement membrane and basal/myoepithelial differentiation (protective-associated)

- **Direction:** better OS.
- **Representative supporting genes (protective HRs):** TP63 (0.810), COL17A1 (0.798), LAMA2 (0.830), COL14A1 (0.824), DST (0.807), RELN (0.796), CLDN11 (0.819), ADAMTS8 (0.793), OGN (0.807), OMD (0.829), IGFBP6 (0.828), MFAP4 (0.834), LRFN5 (0.803), PCDH18 (0.825), IGSF10 (0.824), CPED1 (0.830), RLN2 (0.824), CBX7 (0.831).
- **Pathway references:** GO cellular component "extracellular region" (CD1E, COL17A1, IGSF10, MFAP4, OGN among others); Reactome "extracellular matrix organization," "collagen formation," "laminin interactions."
- **Why these genes together indicate the program:** TP63 is the master myoepithelial/basal transcription factor; COL17A1, COL14A1, LAMA2, DST, ADAMTS8, OGN, OMD, MFAP4, IGFBP6 and the small leucine-rich proteoglycans describe a basement-membrane/ECM environment characteristic of well-organized, myoepithelium-supported normal/luminal-like glandular structures. CLDN11 (tight junction), RELN (ECM signaling) and CBX7 (Polycomb repressor that maintains differentiation) reinforce a differentiated, growth-restrained phenotype.
- **Strength and limitations:** This is the largest protective program (~18/48 protective genes) and is internally very coherent. However, a strong "ECM/differentiation" signature can either reflect (i) a more differentiated tumor biology or (ii) stromal/myoepithelial contamination of the tumor sample. Without microdissection or paired histology, the two cannot be separated from expression alone (see §6).

### Program D — Translational and epitranscriptomic up-regulation (risk-associated)

- **Direction:** worse OS.
- **Representative supporting genes:** LARP1 (1.261 — top HR in the dataset), YTHDF1 (1.192), UHRF1 (1.209), RALGAPB (1.207), EZR (1.227), DDX41 (1.191), STIP1 (1.237), PSMD3 (1.183), ZFP91 (1.183), TRIB3 (1.191), RMND5B (1.198), UTP23 (1.203), FAF2 (1.200), HACD3 (1.197), GPI (1.192).
- **Pathway references:** GO MF "RNA binding" (LARP1, YTHDF1, DDX41, EZR, NUSAP1 etc. — retrieved recurrence); Reactome "mRNA processing/translation," KEGG "proteasome."
- **Why these genes together indicate the program:** LARP1 is a direct mTORC1 substrate that stabilizes 5′-TOP mRNAs encoding ribosomal proteins; YTHDF1 is an m⁶A reader that promotes translation of marked transcripts; UHRF1 couples DNA methylation maintenance to S-phase; EZR (ezrin) anchors translation/signaling at the cortical cytoskeleton; STIP1 is an Hsp70/Hsp90 co-chaperone frequently co-opted by cancer; the proteasomal PSMD3 and E3-ligase regulators FAF2/ZFP91/TRIB3 add a protein-homeostasis/remodeling axis. The aggregate is a high translational-output, stress-adapted, growth-factor-responsive state.
- **Strength and limitations:** Program D is supported by a clear RNA-binding annotation cluster but is more heterogeneous than A or B and partly overlaps with Program A through shared cell-cycle effectors (UHRF1, NUSAP1). Direction is consistent and statistically strong in-cohort; external clinical evidence is contextual only.

### Program E — Calcium/cytoskeletal signaling and stress-adapted metabolism (risk-associated)

- **Direction:** worse OS.
- **Representative supporting genes:** ATP2A2 (1.238 — SERCA2), EZR (1.227), GSK3B (1.227), STIP1 (1.237), CPT1A (1.196), GPI (1.192), CFL1 (1.191), ADGRG1 (1.205), GPRC5A (1.202), WNT7B (1.183), S100P (1.196), ALG3 (1.187), MYORG (1.192), TBC1D24 (1.188), TBC1D31 (1.195), USP30 (1.222).
- **Pathway references:** GO MF "ATP binding" (ABCB1, AK3, ATP2A2, DDX41, KIF20A among others); Reactome "ion homeostasis / Ca²⁺ signaling," "Wnt signaling," "glycolysis."
- **Why these genes together indicate the program:** ATP2A2 (SERCA) maintains ER Ca²⁺ stores that drive proliferation and ER stress responses; GSK3B integrates Wnt, PI3K and insulin signals and has been linked to BC outcome; CPT1A fuels fatty-acid β-oxidation in stress-adapted cells; GPI commits glycolysis to lactate; GPRC5A and ADGRG1 are orphan/adhesion GPCRs; WNT7B is a non-canonical Wnt ligand; CFL1/EZR remodel actin; USP30 is a mitochondrial deubiquitinase. The program reads as a metabolically and mechanically active, stress-tolerant, signaling-bias toward proliferation.
- **Strength and limitations:** Largest individual HR (ATP2A2, GSK3B, EZR) and several known BC-relevant nodes (GSK3B, GPRC5A — there is gastric-cancer literature support retrieved for GPRC5A), but functionally heterogeneous and the most "association-only" of the five; whether this is a single coordinated program or several overlapping ones cannot be resolved without a co-expression/regulatory analysis.

> Cross-program note: Programs D and E overlap mechanistically through EZR, GSK3B and STIP1, and A bleeds into D via UHRF1/NUSAP1/DDX41. They are reported as separate programs because their therapeutic angles (translation inhibition vs. metabolic/Ca²⁺ targeting vs. mitotic kinase inhibition) are distinct.

---

## 3. Key genes and interaction modules (≤10)

The following ten represent the highest-yield nodes, ranked by (i) statistical strength in this cohort, (ii) coherence with at least one named program above, and (iii) external evidence density.

1. **AURKA (HR 1.189; risk)** — Aurora-A mitotic kinase; central to Program A. Co-membership/STRING neighborhood with KIF4A, NUSAP1, PRC1 (TPX2-hub) and with CDC20, KIF20A, PKMYT1 (PLK1-hub). Many small-molecule AURKA inhibitors exist (clinicaltrials records returned). Relationship: pathway co-membership and documented physical interaction with TPX2; the four-way STRING neighbors are not necessarily direct interactors with AURKA itself.
2. **CDC20 (HR 1.191; risk) + UBE2C (1.210) + UBE2S (1.184)** — APC/C activating module, Program A. STRING places all three as ANAPC2-neighbors; UBE2C and UBE2S are well-known direct physical partners of APC/C. Co-membership and direct biochemical relationship.
3. **TPX2 (HR 1.202; risk) / KIF4A (1.199) / PRC1 (1.186) / NUSAP1 (1.194)** — Spindle assembly module, Program A. TPX2-AURKA and KIF4A-chromatin are direct interactions in the literature; PRC1 and NUSAP1 are pathway co-members.
4. **PKMYT1 (HR 1.244; risk)** — Wee1-family kinase inhibiting CDK1; G2/M gatekeeper (Program A). PLK1-hub STRING neighbor of AURKA/CDC20/KIF20A. PKMYT1 inhibitors are in oncology development (clinicaltrials/CIViC records); relationship to others is pathway co-membership, not direct binding.
5. **LARP1 (HR 1.261; risk — top in the cohort)** — mTORC1 effector driving 5′-TOP mRNA translation (Program D). Co-membership with the RNA-binding module (YTHDF1, DDX41, EZR, NUSAP1) — co-expression/co-pathway, not direct physical interaction.
6. **GSK3B (HR 1.227; risk)** — Multi-pathway kinase bridging Programs D/E; documented physical interactors in STRING include AXIN1/AXIN2/CTNNB1/APC (Wnt destruction complex, all at 0.999) — these are *direct physical interactions* with GSK3B, but the BC-relevant prognostic signal here is association, not the Wnt complex specifically.
7. **TP63 (HR 0.810; protective) + COL17A1 (0.798) + LAMA2 (0.830) + COL14A1 (0.824) + DST (0.807) + RELN (0.796) + ADAMTS8 (0.793)** — Basal/myoepithelial/ECM module, Program C. Co-expression/co-membership within breast basal cells; p63 directly transactivates basal keratins and basement-membrane genes (direct regulatory relationship documented externally). In this dataset they co-vary in the protective direction.
8. **CD1C (HR 0.814) + CD1E (0.824) + FCER1A (0.793) + FLT3 (0.817) + JCHAIN (0.803) + KLRB1 (0.822)** — DC/B/NK module, Program B. Co-membership in lymphoid-lineage transcriptional programs; not direct physical interactors. Their joint protective signal most plausibly reflects immune-cell infiltration rather than tumor-intrinsic expression.
9. **STAT5A (HR 0.806) + STAT5B (0.837) + IL27RA (0.825)** — JAK-STAT5 module, Program B. STRING places STAT5A/B as STAT3-neighbors with FLT3 and LEPR — co-membership evidence. STAT5A/B are partially redundant paralogs with documented direct and regulatory interactions upstream (IL27RA/JAK); the protective direction here is consistent with intact cytokine-driven lymphocyte signaling.
10. **STIP1 (HR 1.237; risk)** — Hsp70/Hsp90 organizing co-chaperone (Program D). STRING-derived Hsp90-client co-membership; published pan-cancer bioinformatics analyses (literature record PMID 37488801) nominate STIP1 as an immune-infiltration–linked prognostic factor — *literature co-occurrence only, not replication of this HR*.

> Important: I have not described any of these as direct physical binders of each other unless the interaction is documented (GSK3B↔AXIN/CTNNB1/APC, AURKA↔TPX2, UBE2C/UBE2S↔APC/C, TP63→basal-keratin/basement-membrane targets). All other relationships above are co-membership/co-expression.

---

## 4. Validation priorities (≤5)

1. **AURKA / TPX2 / CDC20 mitotic module as a therapeutic target in aggressive BC** — *Therapeutic target.*
   - **Why prioritize:** Largest coherent risk program (Program A), multiple drugs in oncology pipelines (clinicaltrials/CIViC records present for some), all top-ranked in this cohort.
   - **Current-dataset evidence:** All three are risk-associated with FDR ≤ 1 × 10⁻⁶; STRING/Reactome co-membership in mitotic networks.
   - **External evidence for/against:** Multiple AURKA inhibitors in trials; PKMYT1 inhibitors also in development. *No survival benefit in unselected BC has been established*; AURKA inhibitor + paclitaxel trials in TNBC have been mixed.
   - **Next step:** Test whether the mitotic-risk gene-set score stratifies response to AURKA/PKMYT1 inhibitors in BC PDX or trial cohorts; check synergy with taxanes.
   - **Status:** **Supported hypothesis** (in-cohort prognostic signal + mechanistic plausibility + drug availability, but no causal/prospective trial evidence).

2. **Combined mitotic-proliferation score as a prognostic biomarker** — *Biomarker.*
   - **Why prioritize:** Per-gene HRs are modest (1.18–1.26); a multi-gene proliferation score would have greater effect size and could complement Ki-67 or gene-expression-based assays (e.g., Oncotype DX, Prosigna).
   - **Current-dataset evidence:** ~25 concordant risk genes with FDR ≤ 10⁻⁶ each; pathway coherence across KEGG Cell cycle and GO:0045840.
   - **External evidence:** Proliferation gene signatures are already validated prognostic biomarkers in BC (PAM50 proliferation, Genomic Grade Index) — *this is not independent replication of the current signature*, only conceptual prior plausibility.
   - **Next step:** Build a mitotic-risk score from this gene set and benchmark against Ki-67, PAM50 and GGIndex in TCGA-METABRIC and SCAN-B; assess added prognostic value in each BC subtype.
   - **Status:** **Supported hypothesis.**

3. **LARP1 / YTHDF1 translational axis in BC outcome** — *Mechanistic hypothesis / therapeutic target.*
   - **Why prioritize:** LARP1 carries the largest single HR (1.261); combines a top in-cohort effect with a tractable mechanistic axis (mTORC1 → 5′-TOP translation; m⁶A-mediated translation).
   - **Current-dataset evidence:** LARP1 (1.261), YTHDF1 (1.192), UHRF1 (1.209), EZR (1.227) are all risk-associated; RNA-binding GO MF retrieved.
   - **External evidence:** LARP1 is an established mTORC1 substrate; YTHDF1 is a known m⁶A reader promoting oncogenic translation; both have pre-clinical cancer biology but no BC-specific prognostic replication supplied.
   - **Next step:** Assess LARP1/YTHDF1 protein expression in a BC TMA, test prognostic independence from proliferation markers, and evaluate sensitivity to mTORC1 inhibitors (everolimus/alpelisib-class agents) in LARP1-high BC models.
   - **Status:** **Exploratory hypothesis.**

4. **Immune-microenvironment signature (CD1C, CD1E, FCER1A, JCHAIN, FLT3, KLRB1) as a favorable-prognosis / immunotherapy-response biomarker** — *Biomarker (with confounding check).*
   - **Why prioritize:** Eight concordant protective genes spanning DCs, B cells and NK/innate T cells; actionable for immunotherapy and for immune-cold/hot stratification.
   - **Current-dataset evidence:** All eight HR < 1 with FDR ≤ 4 × 10⁻⁷.
   - **External evidence:** Immune-rich ("hot") BC tumors consistently have better OS in the literature; CD1C/FCER1A/JCHAIN are not the canonical immune-checkpoint biomarkers (CD8, PD-L1, GZMB), so this may identify a *DC/B-cell-rich* subset with distinct biology.
   - **Next step:** Deconvolve the signature (CIBERSORT/xCell) in BC cohorts, test whether it (a) independently predicts OS after adjusting for tumor-infiltrating lymphocyte density and (b) enriches for response to ICB in BC trials.
   - **Status:** **Supported hypothesis** (in cohort) **with strong confounding/composition caveat** (see §6).

5. **TP63/basal-myoepithelial/ECM program as a marker of better-differentiated, lower-grade BC** — *Confounding / composition check.*
   - **Why prioritize:** This is the largest protective program; before it is accepted as a tumor-intrinsic survival signal, the contribution of stromal/myoepithelial cells and tumor grade must be quantified.
   - **Current-dataset evidence:** TP63 (0.810), COL17A1 (0.798), LAMA2 (0.830), RELN (0.796), DST (0.807) and ~14 other ECM genes co-vary in the protective direction.
   - **External evidence:** TP63 and basal keratins define the basal-like/myoepithelial BC lineage; ECM genes can originate from stromal cells.
   - **Next step:** Restrict the analysis to microdissected tumor epithelium (or to TCGA-BC purity-adjusted expression), adjust for histologic grade and PAM50 subtype, and re-estimate the HRs.
   - **Status:** **Exploratory hypothesis** that requires the composition adjustment before any causal interpretation.

---

## 5. Evidence grounding (summary table)

| Claim | Direct input (HR/FDR) | Pathway/ontology | Network (STRING) | Disease/clinical | Tissue (GTEx/HPA) | Drug/therapeutic | Literature |
|---|---|---|---|---|---|---|---|
| Mitotic risk program (A) | Yes — 25 risk genes, FDR ≤ 10⁻⁶ | GO:0045840, KEGG cell cycle (retrieved) | PLK1-, TPX2-, ANAPC2-, BUB1B-hubs | OpenTargets/cBioPortal return for most genes | Mitotic genes broadly expressed in proliferating tissues | AURKA, PKMYT1 inhibitors in trials (clinicaltrials) | Not directly replicated in this answer |
| Immune protective program (B) | Yes — 8 protective genes, FDR ≤ 4 × 10⁻⁷ | Antigen presentation, JAK-STAT5 | STAT3-hub with FLT3/LEPR/STAT5A/B | OpenTargets/ClinVar returns | DC/B/NK markers — immune tissue-restricted | Possible ICB responder signal | Not directly replicated |
| ECM/myoepithelial program (C) | Yes — 18 protective genes, FDR ≤ 10⁻⁶ | ECM/collagen/laminin, "extracellular region" | Co-expression; few strong STRING edges among them | BC basal-lineage association (external) | Myoepithelial/basal expression (HPA) | No direct drug | Not directly replicated |
| Translational/epitranscriptomic (D) | Yes — LARP1 (HR 1.261), YTHDF1, UHRF1, EZR risk | GO "RNA binding," proteasome | LARP1 co-membership with RNA-binding module | OpenTargets returns | Broad expression | mTORC1 inhibitors exist (clinicaltrials) | LARP1/YTHDF1 cancer biology literature, no supplied BC replication |
| Ca²⁺/cytoskeletal/metabolic (E) | Yes — ATP2A2, GSK3B, STIP1, EZR risk | ATP binding, Wnt, glycolysis | GSK3B high-confidence Wnt-complex edges | OpenTargets/cBioPortal returns | Various | GSK3B inhibitors in trials (non-BC) | Not directly replicated |
| Key gene–gene relationships | Indirect (direction only) | Co-membership for most | Direct physical only for GSK3B↔Wnt complex, AURKA↔TPX2, UBE2C/S↔APC/C | — | — | — | — |

**Independent evidence:** No external-cohort survival statistics were provided. Pathway, network, tissue, drug and literature records are *contextual plausibility*, not replication. Several STRING hubs and the GO "RNA binding" / "ATP binding" modules derive from shared underlying annotation/protein-interaction resources, so they are not fully independent of each other. No conflicting external evidence was identified for the in-cohort directions of Programs A–E.

---

## 6. Limitations and alternative explanations (≤5)

1. **Tissue/cell-composition confounding.** The protective immune and ECM/myoepithelial signals (Programs B and C) almost certainly partly reflect non-malignant cell content: tumor-infiltrating lymphocytes (CD1C, CD1E, FCER1A, JCHAIN, FLT3, KLRB1) and stromal/myoepithelial cells (COL17A1, LAMA2, TP63, RELN). Without purity-adjusted or microdissected expression, their HRs conflate tumor biology with microenvironment composition. **Investigation:** repeat the Cox models with CIBERSORT/xCell deconvolution, EPIC stromal scores, or restrict to high-tumor-purity samples; compare effect sizes across PAM50 subtypes.

2. **Subtype confounding (luminal A vs B vs HER2⁺ vs basal).** Proliferation genes (Program A) are well-known to be upregulated in luminal B / HER2⁺ / basal-like relative to luminal A; immune-cold is more frequent in luminal A. **Investigation:** stratify Cox models by IHC subtype or PAM50 and report whether Program A and Program B retain independent prognostic value within subtype.

3. **Treatment-exposure heterogeneity.** Endocrine therapy, anti-HER2 therapy, and chemotherapy all modulate OS and can interact with proliferation and immune gene expression. If treatment exposure is unbalanced across high/low expressors, HR estimates are biased. **Investigation:** adjust for treatment covariates or restrict to a uniformly treated sub-cohort.

4. **Modest per-gene effect sizes and multiple testing.** Individual HRs are 1.18–1.26 (risk) and 0.79–0.84 (protective); although FDRs are extremely small, the *clinical* magnitude per gene is small. Single-gene inference should be deprioritized in favor of gene-set scores (Programs A and B as candidates). Over-reliance on top-ranked individual genes (LARP1, STIP1, PKMYT1) would overstate biological specificity.

5. **Association vs causation and platform effects.** OS Cox models quantify association between expression and outcome; they do not establish that any gene causally drives survival. Batch/platform differences (RNA-seq vs microarray) and cohort-specific effects could partially drive HRs. **Investigation:** meta-analytic or multi-cohort Cox models; functional perturbation (CRISPRi of LARP1/AURKA/CDC20 in BC lines, then xenograft growth/metastasis assays) for the highest-priority candidates.

> Bottom line: the prognostic signature is statistically robust within this cohort and biologically coherent, but the mitotic risk signal is the most likely to represent true tumor-intrinsic biology, while the immune and ECM signals should be tested for composition and subtype confounding before being accepted as tumor-cell-autonomous prognostic or therapeutic targets.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=110, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
